Condition

Hormone Receptor Positive Breast Carcinoma

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 26 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials26

Recruiting10

Common interventions25

Lead sponsors shown15

Clinical trials

26 shown

Tai Chi for Reducing Aromatase Inhibitor-Induced ArthralgiaNCT07737951 · 2026-07-27

ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast CancerNCT06224673 · 2026-06-05

AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid TumorsNCT07454642 · 2026-03-31

Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal SubtypeNCT06486883 · 2025-06-30

A Study of Revaree Plus in People With Breast CancerNCT07042581 · 2025-06-20

DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer PatientsNCT06388122 · 2024-04-30

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid TumorsNCT06120283 · 2023-12-01

Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 StudyNCT06805812 · 2023-05-01

Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast CancerNCT04553770 · 2020-10-09

Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.NCT04305834 · 2020-03-25

BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire DisorderNCT07596212 · 2026-09-01

NOT_YET_RECRUITING

CLEAR-B: Cancer Landscape - Early Adjuvant Retrospective Registry - Breast CancerNCT05870813 · 2023-03-10

Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or LymphomasNCT05565417 · 2022-11-28

ACTIVE_NOT_RECRUITING

Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast CancerNCT05173103 · 2021-09-24

Oral SM-88 in Patients With Metastatic HR+/HER2- Breast CancerNCT04720664 · 2021-09-22

Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic CancerNCT04498520 · 2021-03-31

Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal TherapyNCT04379570 · 2021-02-15

ACTIVE_NOT_RECRUITING

Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast CancerNCT04762979 · 2021-02-12

ACTIVE_NOT_RECRUITING

Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)NCT04726332 · 2021-02-10

Elacestrant in Preoperative Setting, a Window of Opportunity StudyNCT04797728 · 2021-02-09

Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE StudyNCT04316117 · 2020-09-15

ACTIVE_NOT_RECRUITING

A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast CancerNCT04505826 · 2020-08-13

Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast CancerNCT04305236 · 2020-07-23

A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid TumorsNCT03845166 · 2019-03-20

ACTIVE_NOT_RECRUITING

Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNANCT05814224 · 2018-05-22

A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast CancersNCT03251378 · 2017-12-11

Common interventions

Leading sponsors

Exelixis 2 Alliance for Clinical Trials in Oncology 1 Avacta Life Sciences Ltd 1 BeOne Medicines 1 Centro di Riferimento Oncologico - Aviano 1 City of Hope Medical Center 1 ECOG-ACRIN Cancer Research Group 1 Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 1 Georgetown University 1 Hutchison Medipharma Limited 1 Immunitas Therapeutics 1 Institut fuer Frauengesundheit 1 Jonsson Comprehensive Cancer Center 1 Laura Huppert, MD, BA 1 Marina N Sharifi 1

Trial status mix

RECRUITING10

ACTIVE_NOT_RECRUITING5

COMPLETED4

TERMINATED3

UNKNOWN2

NOT_YET_RECRUITING1

WITHDRAWN1

Phase mix

PHASE211

PHASE19

NA2

EARLY_PHASE11

PHASE31

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.